Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a radiopharmaceutical-focused company whose news flow centers on diagnostic imaging products, radiopharmaceutical pipeline progress and corporate developments. The company describes its purpose as enabling clinicians to "Find, Fight and Follow" disease, and its announcements frequently highlight advances in PET radiodiagnostics, oncology imaging agents and Alzheimer’s disease diagnostics.
News about Lantheus often covers regulatory milestones for its radiopharmaceutical pipeline. Recent releases include U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application for a new formulation of its piflufolastat F 18 PSMA PET imaging agent, a PDUFA date for LNTH-2501 (Ga 68 edotreotide) for somatostatin receptor-positive neuroendocrine tumors, and FDA acceptance of an NDA for MK-6240, a tau-targeted PET imaging agent for Alzheimer’s disease. These updates provide insight into how the company is expanding its diagnostic portfolio in oncology and neurology.
Lantheus news also frequently addresses business development and portfolio shaping. The company has reported acquisitions of Evergreen Theragnostics and Life Molecular Imaging, adding assets such as OCTEVY and Neuraceq and expanding its capabilities across the radiopharmaceutical value chain. It has also announced the divestiture of its SPECT business to SHINE Technologies, along with licensing agreements such as an exclusive deal with GE HealthCare to develop, manufacture and commercialize PYLARIFY in Japan.
Investors and healthcare professionals following LNTH news can also expect quarterly earnings releases, stock repurchase program announcements, leadership transition updates and conference participation notices. Together, these items provide context on Lantheus’ financial performance, capital allocation, governance and strategic direction in the radiopharmaceutical and medical imaging space.
Lantheus Holdings, Inc. (NASDAQ: LNTH) and POINT Biopharma Global, Inc. (NASDAQ: PNT) announced that the FDA has granted Fast Track designation for 177Lu-PNT2002, a radiopharmaceutical therapy for metastatic castration resistant prostate cancer (mCRPC). This designation accelerates the drug's development and review process to address unmet medical needs in this serious condition. The innovative therapy combines a PSMA-targeted ligand with the radioisotope 177Lu. The Phase 3 SPLASH trial is complete, with top-line data expected in the latter half of 2023. Enrollment included patients resistant to standard hormonal therapies who are ineligible for chemotherapy, with follow-up extending up to five years.
Lantheus Holdings (NASDAQ: LNTH) announced a conference call and webcast scheduled for May 4, 2023, at 8:00 a.m. ET to discuss its Q1 2023 financial and operating results. Participants can register online to access the call and are advised to register 15 minutes early to avoid delays. A replay will be available two hours post-webcast, archived for at least 30 days. With over 65 years in the field, Lantheus focuses on enhancing patient outcomes through diagnostics, radiotherapeutics, and AI solutions aimed at disease management. Headquartered in Massachusetts, the company also operates in New Jersey, Canada, and Sweden.
Lantheus Holdings (NASDAQ: LNTH) announced the promotions of Paul Blanchfield to President and Dan Niedzwiecki to Chief Administrative Officer on March 17, 2023. Blanchfield, who previously served as Chief Operating Officer, will oversee commercial and technical operations as well as the medical function. His experience includes significant roles in pharmaceutical management. Niedzwiecki, with over 20 years in legal and business experience, will continue overseeing legal and intellectual property, while also managing human resources and corporate communications. These promotions are expected to support Lantheus’s mission to improve patient outcomes through advanced diagnostics and therapeutic solutions.
Lantheus Holdings, Inc. (NASDAQ: LNTH) reported impressive financial results for 2022, showing a remarkable increase in worldwide revenue of $263.2 million for Q4 and $935.1 million for the full year, which represents growth of 103.1% and 119.9% year-over-year, respectively. The company reported a GAAP net loss of $119.2 million for Q4 but achieved a net income of $28.1 million for the full year. Adjusted fully diluted EPS rose significantly to $1.37 for Q4 and $4.22 for the full year, compared to $0.25 and $0.49 in 2021. Free cash flow also saw substantial growth, standing at $100.6 million for Q4 and $263.4 million for the full year 2022. The company provided a positive outlook for 2023, targeting revenue between $1.140 billion and $1.160 billion.
Lantheus Holdings (NASDAQ: LNTH) presented significant findings on piflufolastat F 18 at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium. This PSMA-targeted radiopharmaceutical is approved for imaging in prostate cancer patients. Notably, in a study, management plans were altered in 39.1% of patients with PSA levels below 0.5 ng/mL, with 74.1% of these cases leading to intensified treatment. The findings underscore the importance of piflufolastat F 18 in tailoring patient management strategies for low PSA levels, potentially improving outcomes for those diagnosed with prostate cancer.
Lantheus Holdings will host a conference call and webcast on February 23, 2023, at 8:00 a.m. ET to discuss its financial results for Q4 and the full year of 2022. Participants are encouraged to register early to avoid delays. A replay will be available approximately two hours after the event.
Lantheus has been in the life sciences field for over 65 years, focusing on diagnostics, radiotherapeutics, and AI solutions to enhance patient outcomes. For further details, visit their official website.
On February 8, 2023, Lantheus Holdings (NASDAQ: LNTH) announced its upcoming presentation of data on piflufolastat F 18 at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco from February 16-18, 2023. The presentation will focus on its efficacy in imaging prostate cancer, particularly in patients with low PSA levels. Dr. Frederic Pouliot will present findings from the CONDOR study during the session titled Changes in planned disease management after piflufolastat F 18 PET/CT. The results indicate significant management changes for nearly two-thirds of patients, highlighting the agent’s clinical utility.
Lantheus Holdings (NASDAQ: LNTH) announced its acquisition of Cerveau Technologies for the clinical-stage PET imaging agent MK-6240, which targets Tau tangles in Alzheimer’s disease. This acquisition diversifies Lantheus' radiopharmaceutical pipeline, providing access to the most widely-used Tau PET agent. MK-6240 is currently involved in over 60 clinical trials globally and can enhance diagnosis and treatment for the estimated 6.5 million Americans with Alzheimer’s. The acquisition includes an upfront payment, potential milestone payments, and double-digit royalties on sales.
Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, President and CEO, will present at the J.P. Morgan 2023 Healthcare Conference on January 11, 2023, at 1:30 p.m. PST. The webcast of the presentation will be accessible via the Investors section of the company’s website, where it will also be replayable for at least 30 days. Lantheus is focused on diagnostics, radiotherapeutics, and AI solutions to enhance patient outcomes and has over 65 years of experience in the healthcare sector.
Lantheus Holdings (NASDAQ: LNTH) announced the successful closing of strategic collaboration agreements with POINT Biopharma Global, aimed at enhancing diagnostics and radiotherapeutics. The closing was subject to standard conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act. With over 65 years of experience, Lantheus continues to focus on improving patient outcomes through innovative solutions. The agreement is expected to strengthen Lantheus' position in the life-changing radiopharmaceutical sector.